Akiram Therapeutics

News

Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.

News

Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.